Proteon logo     Print Page | Close Window

SEC Filings

S-1/A
PROTEON THERAPEUTICS INC filed this Form S-1/A on 10/07/2014
Entire Document
 

Table of Contents

Outstanding Equity Awards at Fiscal Year End

        The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December 31, 2013.

Name
  Notes   Number of
Securities
Underlying
Unexercised
Options
Exercisable(1)
  Number of
Securities
Underlying
Unexercised
Options
Unexercisable
  Option
Exercise
Price ($)(2)
  Option
Expiration
Date
 

Timothy P. Noyes

  (3)     83,742       $ 1.91     8/1/2016  

  (3)     31,505       $ 2.39     9/10/2017  

  (3)     55,829       $ 3.18     6/18/2019  

  (3)     3,479       $ 3.18     12/15/2019  

  (4)     85,388       $ 1.27     10/26/2021  

Steven K. Burke, M.D. 

 

(3)

   
30,411
   
 
$

1.91
   
8/1/2016
 

  (3)     12,287       $ 2.39     9/10/2017  

  (3)     14,898       $ 3.18     6/18/2019  

  (4)     57,934       $ 1.27     10/26/2021  

Daniel P. Gottlieb

 

(3)

   
5,316
   
 
$

2.39
   
9/10/2017
 

  (3)     1,855       $ 3.18     6/18/2019  

  (4)     3,780       $ 1.27     10/26/2021  

  (5)     630       $ 22.22     3/25/2023  

(1)
All of the outstanding option awards were granted under and subject to the terms of our 2006 Equity Incentive plan, described below under "—Equity Benefit and Stock Plans." Except as otherwise indicated, as of December 31, 2013, each option award is immediately exercisable but is subject to repurchase by us until vested. All vesting is subject to the officer's continuous service with us through the vesting dates and the potential vesting acceleration described above under "—Employment Agreements."

(2)
All of the option awards were granted with a per share exercise price equal to the fair market value of one share of our common stock on the date of grant, as determined in good faith by our board of directors

(3)
These grants are fully vested.

(4)
The unvested shares under this option are scheduled to vest in approximately equal quarterly installments through October 1, 2015.

(5)
The unvested shares under this option are scheduled to vest in approximately equal quarterly installments through January 1, 2017.

124